New Mexico Educational Retirement Board Boosts Stock Position in Humana Inc. (NYSE:HUM)

New Mexico Educational Retirement Board lifted its holdings in Humana Inc. (NYSE:HUMFree Report) by 6.6% in the third quarter, HoldingsChannel reports. The firm owned 6,482 shares of the insurance provider’s stock after purchasing an additional 400 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Humana were worth $3,154,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of Humana by 102,197.0% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 13,241,321 shares of the insurance provider’s stock valued at $5,920,592,000 after purchasing an additional 13,228,377 shares in the last quarter. State Street Corp grew its holdings in shares of Humana by 2.5% in the second quarter. State Street Corp now owns 5,852,050 shares of the insurance provider’s stock valued at $2,621,731,000 after purchasing an additional 143,883 shares in the last quarter. Capital World Investors lifted its position in Humana by 18.7% in the second quarter. Capital World Investors now owns 2,322,684 shares of the insurance provider’s stock worth $1,038,513,000 after buying an additional 366,007 shares during the last quarter. Geode Capital Management LLC lifted its position in Humana by 2.6% in the second quarter. Geode Capital Management LLC now owns 2,293,170 shares of the insurance provider’s stock worth $1,022,332,000 after buying an additional 58,693 shares during the last quarter. Finally, Morgan Stanley lifted its position in Humana by 20.8% in the fourth quarter. Morgan Stanley now owns 1,688,442 shares of the insurance provider’s stock worth $864,804,000 after buying an additional 290,865 shares during the last quarter. 91.86% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of Humana stock opened at $447.76 on Thursday. The firm has a market cap of $55.12 billion, a P/E ratio of 18.56, a P/E/G ratio of 1.04 and a beta of 0.48. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.56. Humana Inc. has a 12 month low of $423.29 and a 12 month high of $541.21. The stock’s fifty day moving average price is $476.61 and its 200-day moving average price is $478.65.

Humana (NYSE:HUMGet Free Report) last announced its quarterly earnings results on Wednesday, November 1st. The insurance provider reported $7.78 EPS for the quarter, beating the consensus estimate of $7.15 by $0.63. The firm had revenue of $26.42 billion for the quarter, compared to analyst estimates of $25.57 billion. Humana had a return on equity of 21.03% and a net margin of 2.95%. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter last year, the firm posted $6.88 earnings per share. On average, equities research analysts expect that Humana Inc. will post 28.29 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be paid a $0.885 dividend. The ex-dividend date is Thursday, December 28th. This represents a $3.54 annualized dividend and a yield of 0.79%. Humana’s dividend payout ratio (DPR) is presently 14.68%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on HUM shares. StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 3rd. Stephens lowered their price target on Humana from $575.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd. Jefferies Financial Group raised their price target on Humana from $580.00 to $586.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. JPMorgan Chase & Co. lowered their price target on Humana from $593.00 to $575.00 and set a “neutral” rating for the company in a research report on Friday, November 17th. Finally, Oppenheimer reiterated an “outperform” rating and set a $630.00 target price on shares of Humana in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $587.00.

Check Out Our Latest Stock Report on HUM

About Humana

(Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Stories

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.